Literature DB >> 16877702

Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?

Terry J Gaymes1, Rose Ann Padua, Marika Pla, Stephen Orr, Nader Omidvar, Christine Chomienne, Ghulam J Mufti, Feyruz V Rassool.   

Abstract

Histone deacetylase inhibitors (HDI) increase gene expression through induction of histone acetylation. However, it remains unclear whether increases in specific gene expression events determine the apoptotic response following HDI administration. Herein, we show that a variety of HDI trigger in hematopoietic cells not only widespread histone acetylation and DNA damage responses but also actual DNA damage, which is significantly increased in leukemic cells compared with normal cells. Thus, increase in H2AX and ataxia telangiectasia mutated (ATM) phosphorylation, early markers of DNA damage, occurs rapidly following HDI administration. Activation of the DNA damage and repair response following HDI treatment is further emphasized by localizing DNA repair proteins to regions of DNA damage. These events are followed by subsequent apoptosis of neoplastic cells but not normal cells. Our data indicate that induction of apoptosis by HDI may result predominantly through accumulation of excessive DNA damage in leukemia cells, leading to activation of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877702     DOI: 10.1158/1541-7786.MCR-06-0111

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

1.  Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.

Authors:  Girija Dasmahapatra; Dmitry Lembersky; Minkyeong P Son; Elisa Attkisson; Paul Dent; Richard I Fisher; Jonathan W Friedberg; Steven Grant
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

Review 2.  Fetal Hemoglobin Induction by Epigenetic Drugs.

Authors:  Donald Lavelle; James Douglas Engel; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2018-04-22       Impact factor: 3.851

3.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

4.  Resistance, epigenetics and the cancer ecosystem.

Authors:  Stephen B Baylin
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

Review 5.  Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.

Authors:  S Spiegel; S Milstien; S Grant
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

6.  Sodium arsenite modulates histone acetylation, histone deacetylase activity and HMGN protein dynamics in human cells.

Authors:  Tzutzuy Ramirez; Jan Brocher; Helga Stopper; Robert Hock
Journal:  Chromosoma       Date:  2007-11-13       Impact factor: 4.316

7.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

8.  The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

Authors:  Yun Dai; Shuang Chen; Maciej Kmieciak; Liang Zhou; Hui Lin; Xin-Yan Pei; Steven Grant
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

9.  Replication independent DNA double-strand break retention may prevent genomic instability.

Authors:  Narisorn Kongruttanachok; Chutipa Phuangphairoj; Araya Thongnak; Wanpen Ponyeam; Prakasit Rattanatanyong; Wichai Pornthanakasem; Apiwat Mutirangura
Journal:  Mol Cancer       Date:  2010-03-31       Impact factor: 27.401

10.  Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.

Authors:  S R Green; A K Choudhary; I N Fleming
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.